Scinai Immunotherapeutics (SCNI) revenue and earnings history
Scinai Immunotherapeutics reported revenue of $1.31M for fiscal 2025 (year ended Dec 31, 2025), +99.2% on the year before, and net income of −$8.31M.
Over 1 years, from fiscal 2024 to fiscal 2025, revenue grew at a compound rate of +99.2% a year.
Revenue and net income, 5 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $1.31M+99.2% | −$7.54M | −$8.31M | −$6.03M | $24K | −$6.05M | $303K | — | — | $1.66M | — | 20-F |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Scinai Immunotherapeutics (SCNI) on OQRO.
Common questions
What was Scinai Immunotherapeutics's revenue in fiscal 2025?
$1.31M for the year ended Dec 31, 2025, as reported in its 20-F filed Apr 1, 2026. That is +99.2% on fiscal 2024 ($658K).
How fast has Scinai Immunotherapeutics's revenue grown?
From $658K in fiscal 2024 to $1.31M in fiscal 2025: a compound annual growth rate of +99.2% over 1 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Scinai Immunotherapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
